Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) surged 25.82% to $9.6 in the after-hours session following the reports that it has entered into a non-exclusive distribution agreement with Gabriel Science, LLC for the sale of Microcyn Technology products into the dental market and it has already taken its first order.
Sonoma manufactures Endocyn, a Microcyn Technology product, a biocompatible root canal irrigant that is non-staining for teeth or restorations. According to a study published in the Journal of Endodontics, Regenerative Endodontics by the Departments of Endodontics at Louisiana State University School of Dentistry, Endocyn showed less toxicity than sodium hypochlorite.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The full study can be found here: https://www.sciencedirect.com/science/article/abs/pii/S0099239917310439
Dr. Mark Fontenot, the managing member at Gabriel Science, LLC, said, “we believe Endocyn and the Microcyn family of products are the next generations of hypochlorous acid products that can assist in the treatment of a diverse range of dental, head and neck conditions.”
Amy Trombly, CEO of Sonoma Pharmaceuticals, said, “This is an exciting development in dental technology on our part, to expand our offerings of Microcyn-powered dental products available in the U.S. market.”
Read More
